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ABSTRACT 
This study aimed to provide evidence on whether children at risk of gastrointestinal 
inflammation have increased measurements of faecal calprotectin (FC). Faecal calprotectin 
was measured in 232 children; 55 children (n=11 treatment naïve) with juvenile idiopathic 
arthritis (JIA), 63 with coeliac disease (CD); 17 with new diagnosis before and after 
treatment on gluten free diet and 114 controls. None of the treatment-naive children with JIA 
had raised FC. Four JIA patients on treatment had a raised FC but in all cases a repeat test 
was normal. In newly diagnosed CD patients, the median (IQR) FC was higher 36.4 (26-61) 
than in controls 25.0 (23-41) mg/kg (p=0.045) but this significantly decreased 25 (25-25) 
mg/kg (p=0.012) after six months on gluten free diet.  Random measurements of FC are not 
raised in children with JIA or CD. A significant elevation of FC in these groups is not 
explained by their diagnosis and therefore needs further investigation. 
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What is known 
 Faecal calprotectin is an established biomarker for the differential diagnosis of 
inflammatory bowel disease 
 
What is new  
 Faecal calprotectin, in spot samples, is not raised in children with treated or untreated 
juvenile idiopathic arthritis or coeliac disease 
 Repeatedly elevated measurements of faecal calprotectin in these groups are likely to be 
clinically significant and should prompt initiating investigations for inflammatory bowel 
disease. 
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INTRODUCTION 
Faecal calprotectin (FC) has become an established biomarker for the differential diagnosis of 
inflammatory bowel disease (IBD) (1). National guidelines advocate  the use of FC testing in 
clinical practice, reducing the number of unnecessary referrals and expensive diagnostic 
procedures in specialist centres (2). As the number of assessments for colonic inflammation is 
likely to increase in individuals with other gastrointestinal diseases, or in individuals at risk 
of developing IBD, evidence is required as to whether the clinical benefit of such practice 
balances the associated analytical costs and resource allocation.  
This study aimed to provide preliminary evidence on whether spot measurements of 
FC are raised in certain groups of children at risk of gastrointestinal inflammation. We 
measured FC in children with different types of juvenile idiopathic arthritis (JIA) and in 
children with coeliac disease (CD) prior to and during treatment with gluten free diet (GFD).   
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METHODS 
Participants 
Faecal calprotectin concentration was measured in 242 samples in the different groups of 
children. These were samples collected from: 
a. Seventeen children with newly diagnosed CD, before and after (n=13) six month 
treatment on GFD. Children with CD disease were diagnosed according to the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition diagnostic 
recommendations. All children had raised  IgA tissue Transglutaminase antibodies and 
endomysial testing suggestive of CD  (3). 
b. Forty six children with longstanding CD on treatment with GFD diet for longer than 12 
months [disease duration, median (IQR): 3.1 (1.7 to 7.3) years]. 
c. Eleven children with newly diagnosed, treatment-naïve JIA and 44 others on disease 
modifying treatment [disease duration, median (IQR): 4.1 (2.0 to 7.2) years] including 
biologic therapies. The JIA patients consisted of 7 (13%) with psoriatic arthritis, 13 (24%) 
with enthesitis related arthritis, and the remaining 35 with other types of arthritis. Nine of the 
forty patients with available measurements were positive for Human Leukocyte Antigen B27 
(HLA-B27). The number (%) of children on treatment with methotrexate, biologics, oral 
steroids and steroidal injections were 27 (61%), 16 (36%), 4 (9%) and 9 (20%) respectively. 
Six (14%) of the children were using non-steroidal anti-inflammatory drugs and two (5%) 
were on azathioprine. None of these children reported chronic gastrointestinal symptoms or 
was under investigations for IBD. Four of the JIA children were on modifying treatment and 
one from the treatment naïve JIA patients had a parent with IBD (Table 1).     
d. One hundred and fourteen healthy children with no previous history of gastrointestinal 
disorders acted as reference range. Of these, 22 were siblings of patients with CD with 
negative IgA tissue Transglutaminase antibodies.  
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Measurement of calprotectin 
Faecal calprotectin concentration was measured in samples using the CALPROLABTM 
Calprotectin ELISA (CALPRO, Norway) kit(4). The lower detection limit of the assay is 25 
mg/kg. In children with CD, gastrointestinal symptoms were assessed with the validated 
PedQL™ Gastrointestinal Symptoms Scale. 
 
Statistical analysis 
Differences in FC between groups were compared with Mann-Whitney and Kruskal-Wallis 
tests or chi squared test for FC classes (i.e. normal vs raised). Correlations between FC and 
continuous parameters were explored with Spearman rank correlation. The FC results were 
classified into three groups, between 25 to 50 mg/kg which is the manufacturer’s reference 
threshold, between 50 to 100 mg/kg and higher than 100 mg/kg as the latter has been 
recommended by the National Institute for Health and Care Excellence in UK as a cutoff with 
improved diagnostic accuracy(2). Statistical analysis was performed with Minitab 16 
(Minitab Ltd, Coventry, UK) and MedCalc 15.6. 
 
Ethical approval 
All studies were approved by the West of Scotland, Research Ethics Committee and the 
Research and Development office at NHS Greater Glasgow and Clyde. Every participant or 
their careers, received written information prior to giving signed consent. 
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RESULTS 
Children with JIA  
None of the newly diagnosed, treatment-naïve children with JIA had a FC higher than 100 
mg/kg (Figure 1), with the large majority of participants (64%) presenting values below the 
detection limit of the assay (i.e. 25 mg/kg). Of the JIA patients on disease modifying 
treatment, four had FC concentration above 100 mg/kg. All of these four children provided a 
follow up sample for a repeat FC and in all cases this was deemed normal (FC < 100 mg/kg). 
There was no significant difference in median FC concentrations between the enthesitis 
related arthritis, psoriatic arthritis and other types of JIA (Table 1). None of these children 
had a FC concentration higher than 100 mg/kg. There was no significant difference in the 
concentration of FC between users and non-users of non-steroidal anti-inflammatory drugs 
[median (IQR) mg/kg, users vs. non-users; 25 (25-35) vs. 27 (25-46), p=0.177].  
 
Children with CD  
There was no significant difference in the median concentration (Table 1) or proportion 
(Figure 1) of raised FC between children with longstanding CD and controls. In children with 
newly diagnosed CD, the median (IQR) of FC was significantly higher [36.4 (26-61) mg/kg] 
than in healthy controls [25.0 (23-41) mg/kg]; p=0.045 (Table 1) but none of these children 
had FC higher than 100 mg/kg (Figure 1). There was no significant correlation between FC 
and tissue transglutaminase antibodies (r=0.073; p=0.556) in the CD group. Similarly, for 
both the newly diagnosed (r=-0.227; p=0.383) children and those with longstanding CD 
(r=0.145; p=0.360), no associations were found between FC and the PedQL™ 
Gastrointestinal Symptoms Scale. 
Thirteen children with newly diagnosed CD provided samples 6 months after 
treatment on GFD. In this group, the median (IQR) concentration of FC significantly 
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decreased [36.5 (26-61) vs 25 (25-25) mg/kg; p=0.012] and in all, but two (85%), this was 
below the detection limit of the assay (i.e. 25 mg/kg) at 6 month follow up (Figure 2). 
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DISCUSSION 
There are few data on the potential clinical benefit of FC measurements in groups of 
individuals with chronic disease at increased risk of gastrointestinal inflammation outside 
IBD. Our hypothesis that children with JIA, have occult colonic inflammation was rejected, 
both in a treatment-naïve cohort of patients as well as in children on disease modifying 
treatment. FC levels were within the normal reference range in JIA children with or without 
increased risk of developing IBD. These findings differ from those by Stoll who observed 
higher concentrations of FC in children with enthesitis related arthritis(5) compared with 
other types of JIA and non-inflammatory conditions controls (Table 2). These opposing 
results may be explained by the low use of non-steroidal anti-inflammatory drugs in our 
participants and in accordance with previous research which suggests transient increases in 
FC during regular use of non-steroidal anti-inflammatory drugs(6). In our group, use of non-
steroidal anti-inflammatory drugs was uncommon and intermittent. Transient increase of FC 
in four of our JIA patients might also be explained by concurrent subclinical gastrointestinal 
infection although we did not specifically look for this, at this study. Considering the findings 
of the current study, along with the inherent risk of IBD in this population, and early evidence 
which suggests that some JIA children with increased FC may suffer from subclinical IBD 
(7), we propose referral for further investigations only when FC remains significantly 
elevated in repeated measurements of FC, particularly in the absence of overt gastrointestinal 
symptoms.  
     In this study, FC was measured in two groups of patients suffering from CD; new patients 
at diagnosis, before and after six months on GFD, and others with longstanding disease. Our 
data suggest that while FC was on the whole within the normal range, its median 
concentration at disease diagnosis was significantly higher than in healthy controls, but 
decreased after six months of GFD. These results are in accordance with previous research 
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published by others in children and adults and is summarised in Table 2. Similar to what we 
have shown here, in these previous studies (8-11) no clear associations were observed 
between FC disease activity markers, IgA tissue Transglutaminase antibodies and FC levels 
(Table 2). On the bases of the findings of the current study and previous research (Table 2), 
we propose that FC has no value in the routine diagnostic work-up of CD. A slightly raised 
FC may be explained by false elevation due to mild inflammation of the rectal mucosa from 
nutrient malabsorption or passage of residual antigenic fragments of gliadin through the colon 
and rectal inflammation(12).  
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Conclusion  
Spot measurements of FC are within normal levels in paediatric patients with JIA or CD. A 
significant elevation of FC in this group is not explained by the underlying diagnosis and 
therefore needs further investigation to exclude IBD which can occur in association with both 
JIA and CD.  
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Figure legends 
Figure 1: Faecal calprotectin concentration in paediatric patients at risk of gastrointestinal 
inflammation 
Figure 2: Concentration of faecal calprotectin in patients with coeliac disease prior to and 
after six months on gluten free diet   
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None of the newly diagnosed, treatment-naïve children with JIA had a FC higher than 100 
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decreased [36.5 (26-61) vs 25 (25-25) mg/kg; p=0.012] and in all, but two (85%), this was 
below the detection limit of the assay (i.e. 25 mg/kg) at 6 month follow up (Figure 2). 
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Figure legends 
Figure 1: Faecal calprotectin concentration in paediatric patients at risk of gastrointestinal 
inflammation 
Figure 2: Concentration of faecal calprotectin in patients with coeliac disease prior to and 
after six months on gluten free diet   
Figure 1 Click here to download Figure Figure 1.tif 
Figure 2 Click here to download Figure Figure 2.tif 
Table 1:  Demographic characteristics, and concentration of faecal calprotectin in children at risk of colonic inflammation and healthy controls 
Groups 
 
N 
Gender 
(F/M) 
Age, years 
(median, IQR) 
FC (mg/kg) 
(median, IQR) 
Coeliac disease     
Treated CD 46 26/20 8.9 (6.2-11.2) 25 (25-47) 
Raised tTG-IgA 10    
 
Treatment naive CD 
17 9/8 10.3 (6.5-12.4) 36 (26-61)* 
Raised tTG-IgA 17    
 
Juvenile idiopathic arthritis 
    
Treatment naïve JIA 11 5/6 5.1 (1.9-9.2) 25 (25-41) 
Raised CRP (>7 mg/L) 2    
     
Treated JIA 44 29/15 10.5 (8.6-12.9) 25 (25-45) 
Raised CRP (>7 mg/L) 4    
 
HLA B27+ 
9   25 (25-48) 
 
Enthesitis related arthritis 
13   25 (25-27) 
 
Psoriatic arthritis 
7   27 (25-56) 
Parental history of IBD 4    
Other blood relatives with IBD 4    
 
Other 
    
 
Healthy children 
92 48/44 8.3 (5.6-10.7) 25 (25-41) 
 
Siblings of CD 
22 12/10 9.0 (6.8-11.9) 26 (25-40) 
* vs healthy children, p=0.045 
Table 1
 
Table 2: Evidence table of studies in faecal calprotectin in patients with coeliac disease and juvenile idiopathic arthritics  
 
Publication Participants Results* Association with FC 
Capone, et al. 2014 Adults; NDCD: n=50, HC: n=50 FC (μg/g), HC: 45.1 (38.4), NDCD: 57.7 (29.1); p=NS 
 
Raised FC (>75 μg/g), NDCD: 10% compared with HC, 
8%; p=NS 
No association between FC 
with clinical symptoms, Marsh 
score, tTG 
Balamtekın, et al. 2012 Children; NDCD: n=31 (GI 
symptoms n=18, no GI symptoms 
n=13), CD on GFD: n=33, HC n=34 
FC (μg/g), NDCD [117.2 (3.2-306)] higher than HC [9.6 
(1-70)] and GFD CD [3.7 (0.5-58.2)] (p<0.001) 
 
FC in NDCD with GI symptoms higher compared to no 
GI NDCD (p=0.04) 
No association between FC 
with Marsh score, degree of 
neutrophil infiltration 
Ertekin, et al. 2010 Children; NDCD: n=29, HC: n=10 FC (μg/g), NDCD: 13.4 (8.5), HC: 4.3 (3.3), CD GFD for 
1 year: 4.6 (2.7) 
 
FC in NDCD higher than HC (p=0.004); between HC and 
CD GFD (p=0.8) 
 
Reduction in FC levels with GFD (p=0.001) 
FC (μg/g), NDCD with total 
villus atrophy, 13.8 (9.3) vs 
partial villus atrophy, 3.7 (1.8), 
p=0.005 
Montalto, et al. 2007 Adults; CD: n=28, HC: n=30 FC (μg/g), CD: 45.0 (24.2), HC: 36.5 (21.7), p=0.163; 
None of the participants had high FC (i.e.>100μg/g) 
No association with clinical 
symptoms score (p=0.92), 
histological score (p=0.96), 
neutrophil infiltration (p=0.74) 
Stoll, et al. 2011 Children; ERA: n=9, JIA: n=17 
CTD: 9, NIC: n=6 
FC (μg/g), ERA: 171 (34-280), JIA: 51 (36-98, CTD: 26 
(0-38), NIC: 80 (28-120) 
 
Raised FC levels was high (i.e.>121μg/g) in 
proportionally more ERA patients compared to other 
groups (p=0.024) 
No association between FC 
and NSAID use; One out of 
three patients with GI 
symptoms had raised FC 
 
* Mean (SD) or median (Q1-Q3); NDCD: Newly diagnosed Coeliac Disease; HC: Healthy controls; FC: Faecal calprotectin; GFD: Gluten free diet; GI: 
gastrointestinal symptoms; NS: Non-statistically significant; tTG: IgA tissue transglutaminase antibodies; ERA: Enthesitis related arthritis, JIA: Other 
JIA, CTD: unrelated connective tissue diseases, NIC: Non-inflammatory controls, NSAID: Non-steroidal anti-inflammatory drugs     
Table 2
